Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Early problems in processing knowledge-based information linked to Alzheimer's disease

Early problems in processing knowledge-based information linked to Alzheimer's disease

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Cancer-associated inflammation boosts ADAR1 enzyme activity

Cancer-associated inflammation boosts ADAR1 enzyme activity

CNIO creates 2 new databases to study the human genome

CNIO creates 2 new databases to study the human genome

Researchers identify possible heredity mechanism that predisposes children to ALL

Researchers identify possible heredity mechanism that predisposes children to ALL

New technique could help develop more-specific, cell-based immune therapies for cancer

New technique could help develop more-specific, cell-based immune therapies for cancer

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

High-risk leukemia patients respond to novel drug

High-risk leukemia patients respond to novel drug

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with CLL

TKI-resistant human leukemia stem cells are the source of genomic instability

TKI-resistant human leukemia stem cells are the source of genomic instability

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Studies examine current treatment standards for patients with clotting disorders

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.